A vision on healthcare and medicine in 2025; customer & patient experiences will change dramatically due to AI, IoT, Cloud driven disruption:

It’s time for your annual checkup! A phlebotomist will conveniently visit you at home in the early morning and take your blood (while you are lying relaxed, since it makes a difference to your metabolome if you are lying or sitting), possibly also collecting samples of saliva as well as urine and stool samples your intelligent toilet was sampling and preserving for later microbiome, metabolome, proteome analytics . The service for onsite blood sampling and the technology is there; see IggBo video.

Mayo Clinic and United Therapeutics Corp. can start construction on the foundation for their proposed lung-restoration center at Mayo’s Southside campus.

Imagine that Baltimore’s street lights automatically came on when they sensed someone was near, collected data about air quality and even alerted police at the sound of a gunshot.

We are feeling so #grateful! #ThankYou Cheryl C. Kagan, Hans Riemer, Carla M. Merritt, Karen McManus, Chris Van Hollen, George Leventhal, Megan Howie, @Judy Costello, @Richard Bendis, C. David Pauza, Selina Yuanyuan Milligan 樊媛媛, Virginia M Crews, Martin Rosendale, Ben Woodard, Susan Prince, Tom Hucker, Tom Wallace, Lynne Stein Benzion, CEcD, and many more for celebrating a monumental #Maryland move to 24000sqft lab+office, where we'll launch a #HIV functional cure!

The best Data Scientists see in a slew of data what matters, communicate why it matters, and instruct others about how strategy and operations must change to address what matters.

How can Johnson & Johnson Innovation (JJI) help you reach your goals? We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a diverse team of science and transaction experts whose goal is to find high potential early-stage innovation and, if on strategy and a fit for Johnson & Johnson, create customized deal structures to help accelerate the science to the patient.

Every marketer wants the perfect story to tell. But if you’re in medicine, you don’t want it to be about yourself.

Earlier this year, vascular surgeon John Martin was testing a pocket-sized ultrasound device developed by Butterfly Network, a startup based in Guilford, Connecticut, that he’d just joined as chief medical officer.

1ST Biotherapeutics, Inc. (1ST Bio), a private Korean biotech company, and Neuraly Inc., a startup from Johns Hopkins School of Medicine, today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson's disease. Recent research has shown that inhibitors to c-Abl could slow the progression of Parkinson's disease. Parkinson's disease, a chronic and progressive movement disorder, is the second most common neurodegenerative disease, affecting nearly one million people in the United States.

A plan to build 12M SF of mixed-use development on a 300-acre site near the Food and Drug Administration's HQ in Montgomery County has been in the works for nearly a decade, and the developer feels confident it can break ground in a matter of months.

Six companies presenting innovative medical device solutions that address significant unmet needs in pediatric health were awarded a total of US$250,000 in grant money in San Jose, Calif. at the Fifth Annual Pediatric Device Innovation Symposium, organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.

United Therapeutics Corp (NASDAQ: UTHR), which has an office in the Research Triangle, has received approval of a new inhalation device from the U.S. Food and Drug Administration (FDA) for use with its drug Tyvaso. Tyvaso, has been the focal point of a number of patent disputes. A treatment for pulmonary hypertension (PAH), the drug generates significant sales for the company.

Diabetes has long been one of the most expensive medical conditions. In 2013 spending on care for people with the disease in the United States topped $100 billion. But it is also one of the most amenable to simple, low-cost behavioral interventions. At Geisinger, we set out to improve the health of diabetic adults by providing them with free, nutritious food and a comprehensive suite of medical, dietetic, social, and environmental services.

Thursday, November 30, 2017 from 6:15 p.m. to 8:30 p.m. at Inova Center for Personalized Health 3225 Gallows Road, Fairfax VA

The Inova Personalized Health Accelerator has made it our mission to increase the speed at which innovation enters the health system.

To celebrate this new venture we’re kicking off with a launch event to inspire, align, and connect our talented professionals, dedicated investor base and up-and-coming innovative startups in the area.

Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.

After seeing the strength of the six finalist projects and evaluating each of the teams' proposals, TEDCO board members decided to up their $300,000 offer, and fund every one of them.

LOCATION: Institute for Bioscience and Biotechnology Research (IBBR), 9600 Gudelsky Dr., Rockville, MD 20850

TIME: Thursday, November 30, 2017 - 3:00pm to 5:00pm

NIIMBL was formed to leverage a $70 million cost-shared agreement sponsored by the National Institute of Standards and Technology (NIST) into a $270 million public-private partnership to promote innovative technologies in bio-manufacturing in America. This information session will provide an overview of NIIMBL and explain how your organization can get involved!

Imagine walking into your doctor appointment and not only receiving a thoroughly researched diagnosis, but a menu of treatment options that match your condition, lifestyle and health goals.

Johns Hopkins Applied Physics Lab is set to begin construction on a new building that will be the Laurel-based facility’s largest.

Until recently, serial entrepreneur Naveen Jain’s most ambitious project was Moon Express, a literal moonshot that aims to land a rocket on our cratered neighbor and use its resources to make other planets livable for humans. His newest mission feels just as profound: create a world without chronic disease.

The University System of Maryland (USM) institutions have released a "Statement Supporting Open Access Dissemination of Scholarship," a joint statement created by the university libraries of all 12 USM campuses. Councils representing the faculty, students, and the presidents of USM's universities have collectively endorsed the statement. The statement explains the potential benefits to researchers who choose to make their works "freely available online either immediately upon completion, or within specified limited periods."

Construction for the biomedical sciences building at the Universities at Shady Grove campus is on schedule, and county leaders are looking forward to landing state funds for new academic programs at the facility.

The JLABS: 5 Years of Innovation report quantifies the impact that JLABS and its companies have had on the innovation ecosystem during the past five-years, including investments raised, jobs created and diversity of leadership.

Want to boost your brain power? Researchers at Johns Hopkins think they have a solution.

There are countless programs out there claiming to help improve your brain function. To date, none of them have been proven to be effective. But researchers at Johns Hopkins recently compared two exercises thought to improve brain power, specifically your working memory (not your IQ), which can help you handle a number of work and school-related tasks easier.

The company is working on a therapy for pancreatic cancer using nanotechnology.

OpGen, Inc. (NASDAQ:OPGN) today announced that it has been awarded a contract from the Centers for Disease Control and Prevention (CDC) to develop smartphone-based clinical decision support solutions for antimicrobial stewardship (AMS) and infection control in low- and middle-income countries. The one-year $860,000 award began September 30, 2017 and funds development and evaluation of cloud-based mobile software. OpGen will work with partners Teqqa, LLC and Universidad El Bosque (UEB) of Bogota, Colombia led by Maria Virginia Villegas, M.D., M.Sc.

The University of Maryland BioPark was honored as the Outstanding Research Park of 2017 at the Association of University Research Parks (AURP) International Conference in Huntsville, Ala., on Oct. 11.

American Gene Technologies (AGT), a private Maryland biotechnology company developing cures and treatments for Infectious diseases, cancers and monogenic disorders hosted a ribbon cutting October 23, 2017 celebrating the grand opening of its new 24,000 sq. ft. laboratory and offices. From its new location, AGT will begin clinical trials for its HIV Functional Cure therapeutic in the next six months.

The new AGT expansion will allow for acceleration of gene and cell therapeutic development laboratories supporting the HIV Functional Cure project that is expected to enter the clinic early next year, as well as to sustain the momentum of phenylketonuria and immuno-oncology therapeutics anticipated for clinical activities in late 2019. These early-stage programs represent substantial assets backed by an impressive IP portfolio. The new offices will support the company’s expected growth through early 2020.

TEDCO today announced six finalists for its first-ever Incubator Challenge, a competition created to identify and reward the best ideas for supporting and growing technology companies in Maryland. The finalists will share their ideas with attendees of the 7th Annual Entrepreneur Expo and Stem Cell Symposium on Wednesday, Oct. 25 at the Hilton Baltimore.

United Therapeutics Corporation (NASDAQ: UTHR) today announced approval by the U.S. Food and Drug Administration (FDA) of a new inhalation device, called the TD-300/A, for use with Tyvaso® (treprostinil) Inhalation Solution (Tyvaso).

South Korea must swiftly work to build up a strong medical big data system as it will form the backbone of future medicine led by personalized and predictive health care, biohealth experts in Seoul said Monday.

When the District’s financially troubled 1776 incubator merged with an out-of-town counterpart recently, it became the latest star of Washington’s tech scene to fade away after a few years in the limelight. The sort of permanence that helped make Silicon Valley a top technology hub has largely eluded the region’s start-up incubators.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that the US Food and Drug Administration (FDA) granted marketing authorization to GlaxoSmithKline's (GSK) herpes zoster vaccine, SHINGRIX, containing Agenus' proprietary immune adjuvant QS-21 Stimulon®. SHINGRIX is indicated for prevention of herpes zoster (also known as shingles) in adults aged 50 years and older. The addition of QS-21 Stimulon helps improve the vaccine's effectiveness by boosting immune response in older adults who often experience age-related decline in immunity.   

Gov. Larry Hogan is supporting Elon Musk and his desire to bring an undergrond hyperloop to the East Coast, and it seems like a bit of the Tesla founder’s social media strategy has rubbed off on the Maryland Republican.

The Kauffman Index of Entrepreneurship series offers in-depth measures of the people and businesses that contribute to America’s overall economic dynamism.

Join Maryland Tech Council CEO, Tami Howie, at the 7th Annual TEDCO's Entrepreneur Expo on October 25, 2017 for a fireside chat with Mike Heslin, the Baltimore Market Manager for Lyft from 4:00 PM - 5:00 PM in Room Key 12.